Observational Prospective Study With Probiotic Supplementation on Infants With FGDI
NCT ID: NCT04944628
Last Updated: 2021-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
36 participants
OBSERVATIONAL
2018-08-15
2018-12-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Digestive and Nutritional Effects of Probiotics Supplementation in Premature Newborns
NCT00290576
Effects of Oral Probiotic Supplementation on the Clinical Status of Very-low-birth-weight Preterm Neonates.
NCT02073214
Efficacy and Safety of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders.
NCT01940913
Probiotics On Resistant Bacteria Colonization In Preterm Receiving Antibiotics
NCT02178267
Probiotics Supplementation and Intestinal Microbiome in Neonates With Gastrointestinal Surgery
NCT03266315
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
FGDIs pathophysiology is multifactorial and may include phycological factors and alterations of the gut physiology including gut microbiota dysbiosis.
Probiotics are proposed as a potential treatment for FGDIs. However, evidence is limited.
A probiotic formula composed of strains Bifidobacerium longum CECT 7894 and Pediococcus pentosaceus CECT 8330 is tested in this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic
Probiotic in liquid format (oil suspension) administered 10 drops once daily for 2 weeks (2x10\^9 cfu/day)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥ 37 weeks of gestation at birth.
* ≥ 2500 g of birth weight.
Exclusion Criteria
* Major medical problems (e. g. immunodeficiencies, developmental problems or genetic abnormalities)
* Gastrointestinal diseases
* Administered with antibiotics for 4 weeks or probiotics for 2 weeks before or during study
1 Month
10 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AB Biotics, SA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maura Sticco, MD
Role: PRINCIPAL_INVESTIGATOR
Azienda Sanitaria Locale Napoli
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Azienda Sanitaria Locale Napoli
Naples, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092.
Benninga MA, Faure C, Hyman PE, St James Roberts I, Schechter NL, Nurko S. Childhood Functional Gastrointestinal Disorders: Neonate/Toddler. Gastroenterology. 2016 Feb 15:S0016-5085(16)00182-7. doi: 10.1053/j.gastro.2016.02.016. Online ahead of print.
Asto E, Huedo P, Altadill T, Aguilo Garcia M, Sticco M, Perez M, Espadaler-Mazo J. Probiotic Properties of Bifidobacterium longum KABP042 and Pediococcus pentosaceus KABP041 Show Potential to Counteract Functional Gastrointestinal Disorders in an Observational Pilot Trial in Infants. Front Microbiol. 2022 Jan 12;12:741391. doi: 10.3389/fmicb.2021.741391. eCollection 2021.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Normocolic ADL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.